PRM-151 is a recombinant human serum amyloid P/pentraxin 2 protein developed by Promedior, a biotechnology company developing therapies for fibrotic diseases using plasma-derived proteins and peptides. Also referred to as PTX2, the therapy is injected intravenously in patients and is showing promise as an effective anti-fibrotic agent which can be used to target several…
In a new study, researchers described the insights and perspectives of patients and caregivers regarding the clinical progression of idiopathic pulmonary fibrosis (IPF), and the needs of both at different disease stages. Their article, titled “The care needs of patients with idiopathic pulmonary fibrosis and their carers (CaNoPy): results of a qualitative…
IPF is a progressive, fatal lung disease in which the alveoli and the lung tissue are damaged, becoming thick and scarred (fibrosis), leading to severe breathing difficulties and compromising oxygen transfer between the lungs and the bloodstream. IPF is characterized by a shortness of breath that gradually worsens,…
In this video from schoolofmedicine, meet Hamish S. Osborne and Christine C. Osborne. Mr. Osborne was diagnosed with IPF and had go to through surgery for a double-lung transplant. After that procedure, the couple became parte of the founding supporters of the Program in Lung Healing.
Boehringer Ingelheim Pharmaceuticals, Inc., recently announced the initiation of a trial to compare the safety, tolerability, and pharmacokinetics of adding pirfenidone (Esbriet) to treatment with OFEV (nintedanib, Boehringer Ingelheim) in patients with idiopathic pulmonary fibrosis (IPF). IPF, a type of interstitial lung disease affecting the tissue that supports the…
In a newly published paper in the Stem Cells Translational Medicine journal entitled Adult Lung Spheroid Cells Contain Progenitor Cells and Mediate Regeneration in Rodents With Bleomycin-Induced Pulmonary Fibrosis, scientists from North Carolina State University discovered a quick and simple method to produce stem cells from…
Read the articles: 1. Pulmonary Fibrosis Study Points to Protective Effects of Vitamin D 2. ‘Organs on Chips’ May Revolutionize Lung, Other Disease Research 3. IPF Patients with Chronic Cough Sought for Phase 2 Clinical Trial …
In a new study, researchers reported a novel role for a receptor at the surface of macrophages (specialized cells of the immune system) in lung fibrosis resolution. The study, titled “TRPV4 Mechanosensitive Ion Channel Regulates LPS-Stimulated Macrophage Phagocytosis,” was published in the…
Learn more about IPF: https://bit.ly/1QiRmr3 Pulmonary Fibrosis News is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of…
Remember to always enjoy life and keep breathing. Read the most recent news on Pulmonary Fibrosis. Click here: https://bit.ly/1lfMsiZ…
Get regular updates to your inbox.
